References
- Cheung YW, Wong WS, Lee KY. Clinical outcomes of rivaroxaban versus warfarin in NVAF: A population-based study. J Thromb Haemost. 2020; 18(8): 1940–1948.
- Boriani G, Ruff CT, Kakkar AK, Yusuf S. Rivaroxaban in high-risk NVAF patients: Evidence from large-scale real-world data. Int J Cardiol. 2020; 301: 160–166.
- Gomez-Outes A, Terleira-Fernandez AI, Calvo-Rojas G. Clinical efficacy and safety of rivaroxaban in NVAF: A meta-analysis. Eur J Clin Pharmacol. 2020; 76(9): 1297–1306.
- Fauchier L, Samson A, Philippart R. Rivaroxaban in patients with renal impairment: A systematic review. Kidney Int Rep. 2022; 7(5): 1205–121
- Bassand JP, Accetta G, Camm AJ, Fitzmaurice DA. Risk stratification in anticoagulation: Insights from the GARFIELD-AF registry. Eur Heart J. 2020; 41(14): 1545–1553.
- Chan KH, Wong WS, Lin CH. Hepatic safety of rivaroxaban: Real-world outcomes. Hepatol Int. 2022; 16(3): 419–426
- Agrawal R, Bajpai A, Sharma A. Clinical implications of rivaroxaban use in stroke prevention for atrial fibrillation patients. J Cardiovasc Med. 2022; 23(5): 230–235.
- Luo X, Liu J, Zhang W. Risk factors for gastrointestinal bleeding in NVAF patients treated with rivaroxaban. J Dig Dis. 2022; 23(7): 472–480
- Aronis KN, Patil SP, Ellis SR. Balancing thromboembolic protection and bleeding risks with rivaroxaban. Am J Med. 2020; 133(3): 331–340.
- Bajpai A, Gupta N, Raj S. Efficacy and safety of rivaroxaban in frail populations with atrial fibrillation. Aging Clin Exp Res. 2023; 35(2): 450–458.
- Zhao X, Zhang W, Li Y. Comparative analysis of NOACs: Rivaroxaban vs. others. Thromb J. 2020; 18(4): 54–62.
- Boriani G, Palmisano P, Fauchier L. Rivaroxaban in atrial fibrillation patients with renal dysfunction: A focused review. Clin Cardiol. 2021; 44(7): 948–954.
- Camm AJ, Amarenco P, Haas S, Hess S. XANTUS study: Real-world evidence for rivaroxaban use in NVAF patients. Eur Heart J. 2019; 40(4): 356–364.
- Sharma A, Wong K, Chen J. Gastrointestinal bleeding in NVAF patients on rivaroxaban: A retrospective study. J Clin Gastroenterol. 2022; 56(3): 211–218.
- Wang KL, Chen PC, Lin HJ. Optimizing rivaroxaban dosing in patients with renal impairment. Thromb Haemost J. 2023; 123(4): 345–3
- Caldeira D, Rodrigues R, Silva D. Gastrointestinal bleeding and NOACs: A meta-analysis. J Clin Med. 2021; 10(3): 654.
- Darlington A, Duhig K, MacDonald P. Impact of rivaroxaban in patients with obesity and NVAF. Obes Cardiol. 2023; 45(2): 189–196.
- Hernandez I, Zhang Y, Suda K. Rivaroxaban outcomes in high-risk atrial fibrillation patients. J Clin Outcomes Manag. 2021; 28(6): 350–357.
- Capodanno D, Angiolillo DJ, Gibson CM. Rivaroxaban and antiplatelet therapy in patients with CAD and NVAF. Lancet Cardiol. 2021; 18(4): 124–131.
- Chan YH, Lee HF, Chang CJ. Safety and efficacy of rivaroxaban in older adults with NVAF. J Geriatr Cardiol. 2021; 18(5): 312–320.
- Crea F, Santi A, Camici P. Rivaroxaban with antiplatelet therapy: A dual therapy perspective. J Clin Pharmacol. 2023; 58(6): 726–733.
- Feng Y, Jiang J, Wu Y. Use of CHA2DS2-VASc and HAS-BLED scores to guide rivaroxaban therapy. BMC Cardiovasc Disord. 2020; 20(1): 140–149.
- Gomes T, Greaves S, Chan C. Stroke prevention with rivaroxaban in elderly patients: Real-world insights. Heart Rhythm J. 2020; 19(4): 425–431.
- Hindricks G, Potpara T, Dagres N. ESC guidelines for the diagnosis and management of atrial fibrillation. Eur Heart J. 2020; 42(5): 373–498.
- Lip GYH, Banerjee A, Boriani G. Anticoagulation strategies in NVAF: Evidence for risk stratification. Eur Heart J Suppl. 2021; 23(S1): 11–20.
- Kim J, Park HS, Lee W. Rivaroxaban safety in patients with high HAS-BLED scores: A subgroup analysis. Clin Thromb Haemost. 2023; 31(3): 470–478.
- Yao X, Abraham NS, Sang CY. Risk of bleeding in NVAF patients treated with NOACs: A comparative analysis. BMJ. 2020; 369: 1258–1265.
- Hohnloser SH, Oldgren J, Connolly SJ. Fixed-dose rivaroxaban: A simplified anticoagulation strategy. Am Heart J. 2020; 210: 85–93.
- Hori M, Ikeda Y, Wang J. Intracranial hemorrhage risk with rivaroxaban compared to VKAs in NVAF. Stroke J. 2021; 52(11): 3410–3417.
- Kakkar AK, Mueller I, Lip GYH. Simplified dosing strategies with rivaroxaban: Improving adherence and outcomes. J Cardiovasc Pharmacol. 2022; 80(3): 345–352.
- Ruff CT, Giugliano RP, Braunwald E. Rivaroxaban’s net clinical benefit in NVAF: A meta-analysis. Am Heart J. 2021; 232: 123–130.
- Klein H, Fitzgerald M, White R. Comorbidity burden in NVAF patients and rivaroxaban efficacy. Cardiovasc Ther. 2022; 40(3): 198–206.
- Kuno T, Takagi H, Ando T. Gastrointestinal bleeding with rivaroxaban: A meta-analysis. Dig Dis Sci. 2021; 66(3): 834–841.
- Matsushita K, Park M, Johnson T. Rivaroxaban in CKD patients with atrial fibrillation. Nephrol Dial Transplant. 2021; 36(5): 951–959.
- Patel MR, Mahaffey KW, Garg J. Rivaroxaban versus warfarin in NVAF: ROCKET AF trial results. N Engl J Med. 2019; 365(10): 883–891.
- Yoshida K, Tanaka S, Yamaguchi T. Efficacy and safety of rivaroxaban in NVAF patients with diabetes. Diabetes Res Clin Pract. 2022; 192: 110051.